An update on the TEMPO-2 trial: the potential of tavapadon to improve outcomes in PD
Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, gives an update on the TEMPO-2 trial (NCT04223193), which is evaluating tavapadon for early Parkinson's disease (PD). Prof. Antonini notes that tavapadon is the first D1-receptor agonist to demonstrate improvements in mobility and functionality in both early and advanced PD. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
▶︎
Ongoing research into foslevodopa/foscarbidopa in PD treatment
▶︎
Rethinking restless legs syndrome treatment: the shift beyond dopamine agonists
▶︎
The evolving concept of synucleinopathies in the era of biomarkers
▶︎
Findings from a Phase I trial of autologous SVF therapy in ALS
▶︎
The development of a deep learning tool to detect drug-resistant epilepsy with EEG
▶︎
She Asks if I Know Coldplay and This Singer Shocks The Street
▶︎
Cardiologist: The Fastest Way to Get Rid of Visceral Fat & Reverse Fatty Liver | Dr. Pradip Jamnadas
▶︎
She Wasn't Even Done Singing Yet When The GOLD Confetti Filled The Stage! 🤩
▶︎
Move Like This After Eating (It Changes Everything)
▶︎
10 Hidden Social Rules in Germany Nobody Warns You About!
▶︎
Imaging & physiology across the high–low CSF pressure spectrum: Navigating diagnostic uncertainty
▶︎
Frankreich - Schweden, Highlights mit Livekommentar | FIFA WM 2026 | MAGENTA TV
▶︎
Nobody Breaks Celebrities Like Rowan Atkinson
▶︎
Worst Plane Landing Fails Caught on Camera
▶︎
Trump wants to be ‘THE LAST PRESIDENT’ - Maggie Haberman
▶︎
The Biggest Lies You’ve Been Told About Diet That Cause Brain Disease (Eat This) | Dr. Georgia Ede
▶︎
This One Muscle Is Destroying Your Leg Circulation (And You Don't Even Know It)
▶︎
Xarelto vs. Eliquis | One Causes Brain Bleeds — and Your Doctor Is Still Choosing Wrong
▶︎
Kroger Health's Jim Kirby Recaps NOURISHING CHANGE '26 (#508)
▶︎